...
首页> 外文期刊>Investigative ophthalmology & visual science >In Vivo Drug Delivery of Low Solubility Drugs from Biodegradable Hydrogel Punctum Plugs
【24h】

In Vivo Drug Delivery of Low Solubility Drugs from Biodegradable Hydrogel Punctum Plugs

机译:从可生物降解的水凝胶点状塞子体内溶解度低的药物的体内药物递送

获取原文

摘要

?Purpose?To examine the pharmacokinetics of various corticosteroid drugs released from hydrogel punctum plugs on the basis of aqueous solubility and drug dose in a preclinical animal model.?Methods?Four different topical ophthalmic corticosteroids (dexamethasone - DX, prednisolone - PD, prednisolone acetate - PA and loteprednol etabonate -LE) were individually suspended in a multi-arm PEG precursor solution and injected into small bore tubing prior to cross-linking. The steroid loaded hydrogel matrix was dried and cut into punctum plugs containing approximately 800 μg of each steroid per plug. The DX plug was additionally prepared at a lower 200 μg dose to study the influence of dose. The plugs were inserted into the inferior canaliculus of beagles and explanted after 7 days to analyze the average drug content released from the plug on a per day basis. A subset was left in place and explanted after 21 days for imaging.?Results?The steroid plugs demonstrated an in vivo daily drug release consistent with their aqueous solubility, as is shown in Figure One. Increasing the dose per plug didn’t change the amount released per day indicating drug saturation in tear fluid drives the kinetics of release from the hydrogel plug. Explanted plug images, as shown in Figure Two, demonstrate that the most soluble drug (PD) completely cleared from the matrix whereas the less soluble drugs (PA and LE) had no visual hydrogel clearance even after 21 days. The DX plug when constrained in the canaliculus demonstrates an in vivo directional drug release from the portion facing the punctal opening which is capable of lavage with replenishing tear fluid.?Conclusions?Preclinical studies of steroid release from punctum plugs demonstrate that plugs containing a higher dose of a given steroid will release the same amount per day and will release drug for a longer duration. Once zone clearance begins at the hydrogel interface then diffusion path length limits saturation solubility creating a tapering effect which is beneficial in corticosteroid therapy and is consistent with eye drop therapy regimens. This understanding of in vivo drug release from biodegradable punctum plugs on the basis of aqueous solubility can be applied to other corticosteroids and many other classes of low solubility drugs currently prescribed as eye drop suspensions. ?View OriginalDownload SlideView OriginalDownload Slide?View OriginalDownload SlideView OriginalDownload Slide? Keywords: 487 corticosteroids ? 557 inflammation ? 445 cataract ?.
机译:目的:根据临床前动物模型中的水溶性和药物剂量,检查从水凝胶泪点塞释放的各种皮质类固醇药物的药代动力学。方法:四种不同的局部眼用皮质类固醇(地塞米松-DX,泼尼松龙-PD,醋酸泼尼松龙) -PA和洛替泼诺依他宝酸酯-LE)分别悬浮在多臂PEG前体溶液中,并在交联之前注入小口径管道中。将负载类固醇的水凝胶基质干燥并切成泪点塞,每个塞含约800μg的每种类固醇。额外准备了200克低剂量的DX塞以研究剂量的影响。将塞子插入比格犬的下泪小管中,并在7天后移植,以分析每天从塞子释放的平均药物含量。结果21天后,将其中一个子集留在原位并移植。结果:类固醇栓塞显示出体内每天的药物释放与其水溶性相符,如图1所示。增加每个塞子的剂量不会改变每天释放的量,这表明泪液中的药物饱和会驱动从水凝胶塞子释放的动力学。如图2所示,外植的栓塞图像表明,即使在21天后,溶解度最高的药物(PD)也会从基质中完全清除,而溶解度较低的药物(PA和LE)则没有可见的水凝胶清除率。 DX栓塞在泪小管中时,表明其面对泪点开口的部位具有体内定向的药物释放能力,能够通过补充泪液进行灌洗。给定的类固醇的每日释放量相同,并且会释放更长的时间。一旦在水凝胶界面开始区域清除,则扩散路径长度将限制饱和溶解度,从而产生逐渐减小的作用,这对皮质类固醇治疗有益,并且与滴眼剂治疗方案一致。基于水溶性的对从可生物降解的泪点塞体内释放药物的理解可以应用于其他皮质类固醇和目前被称为滴眼剂悬浮液的许多其他类别的低溶解度药物。查看原始下载幻灯片查看原始下载幻灯片查看原始下载幻灯片查看原始下载幻灯片关键词:487皮质类固醇? 557发炎? 445白内障

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号